Smart for Life (SMFL)
(Delayed Data from NSDQ)
$0.89 USD
-0.11 (-11.20%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $0.90 +0.01 (1.35%) 5:50 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.89 USD
-0.11 (-11.20%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $0.90 +0.01 (1.35%) 5:50 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Smart for Life, Inc. (SMFL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Smart for Life, Inc. (SMFL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 20.69% and 23.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 12.38% and 8.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -86.36% and 51.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 26.19% and 2.58%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.88% and 3.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?